Main Menu Jump to Page

View Complaint
Retainer Agreement
info@rosenlegal.com

Alkermes shareholders have an opportunity to recover their investment losses.

Click "Join this Class Action" above.

Attorneys

Alkermes plc

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc. (NASDAQ: ALKS) resulting from allegations that Alkermes may have issued materially misleading business information to the investing public.

If you purchased stock in Alkermes and would like to recover your losses, please click "Join This Class Action," above.

Press Release

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc – ALKS

New York, N.Y., November 15, 2018. Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Alkermes plc, Inc. (NASDAQ: ALKS) resulting from allegations that Alkermes may have issued materially misleading business information to the investing public.

On October 30, 2018, the U.S. Food and Drug Administration (“FDA”) released a briefing document concerning Alkermes’ New Drug Application for ALKS 5461 ahead of an FDA advisory committee meeting for the drug. The document revealed that Alkermes “used an abridged 6-item version of the MADRS-10 for the primary endpoint of one of the principal studies” rather than the “10-item diagnostic questionnaire (MADRS-10)” despite the FDA’s “advice explicitly against this plan.” The document also revealed the FDA “disagreed with [Alkermes’] planned strategy to average the MADRS results over several weeks, and recommended use of the MADRS-10EOT, as used in other antidepressant studies and as previously agreed.” On this news, Alkermes stock fell $0.57 per share or over 1.4% to close at $39.80 per share on October 30, 2018.

Then, on November 1, 2018, the FDA advisory committee voted 21 to 2 against the approval of ALKS 5461. It was reported that FDA representatives at the hearing stated the agency told Alkermes not to analyze its data through an average, which it did anyway. On this news, Alkermes stock fell $3.09 per share or over 7.5% to close at $37.74 per share on November 2, 2018.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Alkermes investors. If you purchased shares of Alkermes please visit the firm’s website at https://www.rosenlegal.com/cases-1452.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or zhalper@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      Zachary Halper, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 34th Floor
      New York, NY  10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      lrosen@rosenlegal.com
      pkim@rosenlegal.com
      zhalper@rosenlegal.com
      www.rosenlegal.com